​

VistaGen Therapeutics (VTGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VTGN Stock Forecast

VistaGen Therapeutics (VTGN) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $0.95, with a high of $1.00 and a low of $0.90. This represents a 41.79% increase from the last price of $0.67.

- $1 $2 $3 $4 $5 $6 High: $1 Avg: $0.95 Low: $0.9 Last Closed Price: $0.67

VTGN Stock Rating

VistaGen Therapeutics stock's rating consensus is Hold, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (42.86%), 4 Hold (57.14%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 7 0 4 3 Strong Sell Sell Hold Buy Strong Buy

VTGN Price Target Upside V Benchmarks

TypeNameUpside
StockVistaGen Therapeutics41.79%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts233
Avg Price Target$0.95$4.63$4.63
Last Closing Price$0.67$0.67$0.67
Upside/Downside41.79%591.04%591.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26--5--5
Dec, 2514---5
Nov, 2514---5
Oct, 2514---5
Sep, 2513---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 17, 2025Andrew TsaiJefferies$0.90$0.864.65%34.33%
Dec 17, 2025Stifel Nicolaus$1.00$0.7926.58%49.25%
Nov 17, 2025Paul MattheisStifel Nicolaus$12.00$4.60160.87%1691.04%
Jul 22, 2022Andrew TsaiJefferies$6.00$4.3836.99%795.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 17, 2025JefferiesBuyHolddowngrade
Dec 17, 2025William BlairMarket Performdowngrade
Aug 07, 2023Maxim GroupBuyupgrade
Apr 26, 2022Zacks Investment ResearchHolddowngrade
Feb 18, 2021JefferiesBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-6.25$-7.24$-8.51$-1.52-----
Avg Forecast$-6.38$-6.68$-8.40$-1.60$-1.83$-1.90$-2.05$-1.01$1.23
High Forecast$-2.05$-2.14$-4.96$-1.50$-1.77$-1.34$-1.62$-0.60$2.18
Low Forecast$-13.49$-14.12$-14.87$-1.78$-1.88$-2.85$-2.44$-1.79$0.73
Surprise %-2.04%8.38%1.31%-5.00%-----

Revenue Forecast

$-50M $50M $150M $250M $350M $450M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$1.09M$1.11M$-227.00K$1.06M-----
Avg Forecast$877.30K$1.32M$-403.00K$1.07M$689.33K$632.65K$6.94M$69.85M$260.38M
High Forecast$1.63M$2.46M$-276.03K$1.21M$1.34M$1.01M$11.05M$111.24M$414.64M
Low Forecast$419.24K$632.93K$-641.76K$849.62K$268.57K$433.32K$4.75M$47.84M$178.34M
Surprise %24.19%-16.28%-43.67%-0.26%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-17.93M$-47.76M$-59.25M$-29.36M-----
Avg Forecast$-123.38M$-129.19M$-162.58M$-32.07M$-35.37M$-40.61M$-39.29M$-19.55M$23.81M
High Forecast$-39.64M$-41.50M$-95.99M$-28.94M$-34.31M$-25.98M$-31.35M$-11.54M$42.14M
Low Forecast$-261.07M$-273.36M$-287.80M$-34.49M$-36.42M$-55.23M$-47.22M$-34.60M$14.06M
Surprise %-85.46%-63.03%-63.56%-8.44%-----

VTGN Forecast FAQ

Is VistaGen Therapeutics stock a buy?

VistaGen Therapeutics stock has a consensus rating of Hold, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that VistaGen Therapeutics is a neutral investment for most analysts.

What is VistaGen Therapeutics's price target?

VistaGen Therapeutics's price target, set by 7 Wall Street analysts, averages $0.95 over the next 12 months. The price target range spans from $0.9 at the low end to $1 at the high end, suggesting a potential 41.79% change from the previous closing price of $0.67.

How does VistaGen Therapeutics stock forecast compare to its benchmarks?

VistaGen Therapeutics's stock forecast shows a 41.79% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for VistaGen Therapeutics over the past three months?

  • January 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is VistaGen Therapeutics’s EPS forecast?

VistaGen Therapeutics's average annual EPS forecast for its fiscal year ending in March 2025 is $-1.83, marking a 20.39% increase from the reported $-1.52 in 2024. Estimates for the following years are $-1.9 in 2026, $-2.05 in 2027, $-1.01 in 2028, and $1.23 in 2029.

What is VistaGen Therapeutics’s revenue forecast?

VistaGen Therapeutics's average annual revenue forecast for its fiscal year ending in March 2025 is $689.33K, reflecting a -35.21% decrease from the reported $1.06M in 2024. The forecast for 2026 is $632.65K, followed by $6.94M for 2027, $69.85M for 2028, and $260.38M for 2029.

What is VistaGen Therapeutics’s net income forecast?

VistaGen Therapeutics's net income forecast for the fiscal year ending in March 2025 stands at $-35.366M, representing an 20.45% increase from the reported $-29.362M in 2024. Projections indicate $-40.606M in 2026, $-39.29M in 2027, $-19.548M in 2028, and $23.81M in 2029.